Press Releases

Month Year

Month Year

Get News Alerts by Email

Nov 12, 2021
- Photos 1
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial

-- New, late-breaking data from the Leadless II IDE study confirm the Aveir™ leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms
-- Abbott's Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed
-- Abbott's investigational Aveir leadless pacemaker is currently being evaluated for FDA approval
Nov 10, 2021

New Research Finds Challenges in Symptom Recognition and Diagnostic Testing can impact Patient Satisfaction for People with Vascular Disease

- One in four physicians surveyed feel the "lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease" is a key obstacle to an accurate diagnosis
- Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described "confusion about what I was supposed to do next" as an important barrier to early and accurate diagnosis
- Socioeconomic status, age and gender in underserved communities are contributing factors that impact patients’ access to care

Show per page

© 2026 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.